Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

Javeed Iqbal, Hina Naushad Qureishi, Chengfeng Bi, Jiayu Yu, Alyssa Bouska, Joseph Rohr, Wang Chao, Kai Fu, Wing C. Chan, Julie Marie Vose

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Current genomic technologies have immensely improved disease classification and prognostication of major subtypes of B-cell lymphomas. This novel genetic information has not only aided in diagnosis, but has also revealed a landscape of critical molecular events that determine the biological and clinical behavior of a lymphoma. In this review, we summarized the genetic characteristics of major subtypes of B-cell lymphomas, including diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), and mantle cell lymphoma (MCL). We illustrated how genomic profiling had identified molecular subgroups in DLBCL with varied clinical outcomes, and how a subset of genes defined prognosis in MCL and aided in BL diagnoses. We also highlighted some Phase II/III clinical trials using new therapeutic agents to determine clinical efficacy in novel molecular subgroups with distinct gene expression patterns. We believe that refinement of genomic signatures will require more intensive efforts from the biomedical research community to improve targeted therapy designs and bring a substantial change in the treatment decisions. In the next era of genomic medicine, we anticipate that a clinically and biologically relevant molecular profile of each tumor will be obtained at diagnosis to guide therapy.

Original languageEnglish (US)
Pages (from-to)73-88
Number of pages16
JournalBlood Reviews
Volume30
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

B-Cell Lymphoma
Mantle-Cell Lymphoma
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
Phase III Clinical Trials
Phase II Clinical Trials
Follicular Lymphoma
Biomedical Research
Lymphoma
Therapeutics
Medicine
Technology
Gene Expression
Genes
Neoplasms

Keywords

  • Diffuse large B-cell lymphomas
  • Gene expression profiling
  • Molecular classification
  • Molecular prognosis
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Genomic signatures in B-cell lymphoma : How can these improve precision in diagnosis and inform prognosis? / Iqbal, Javeed; Naushad Qureishi, Hina; Bi, Chengfeng; Yu, Jiayu; Bouska, Alyssa; Rohr, Joseph; Chao, Wang; Fu, Kai; Chan, Wing C.; Vose, Julie Marie.

In: Blood Reviews, Vol. 30, No. 2, 01.03.2016, p. 73-88.

Research output: Contribution to journalArticle

Iqbal, Javeed ; Naushad Qureishi, Hina ; Bi, Chengfeng ; Yu, Jiayu ; Bouska, Alyssa ; Rohr, Joseph ; Chao, Wang ; Fu, Kai ; Chan, Wing C. ; Vose, Julie Marie. / Genomic signatures in B-cell lymphoma : How can these improve precision in diagnosis and inform prognosis?. In: Blood Reviews. 2016 ; Vol. 30, No. 2. pp. 73-88.
@article{e021488e742140aebb14edf03cf2548a,
title = "Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?",
abstract = "Current genomic technologies have immensely improved disease classification and prognostication of major subtypes of B-cell lymphomas. This novel genetic information has not only aided in diagnosis, but has also revealed a landscape of critical molecular events that determine the biological and clinical behavior of a lymphoma. In this review, we summarized the genetic characteristics of major subtypes of B-cell lymphomas, including diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), and mantle cell lymphoma (MCL). We illustrated how genomic profiling had identified molecular subgroups in DLBCL with varied clinical outcomes, and how a subset of genes defined prognosis in MCL and aided in BL diagnoses. We also highlighted some Phase II/III clinical trials using new therapeutic agents to determine clinical efficacy in novel molecular subgroups with distinct gene expression patterns. We believe that refinement of genomic signatures will require more intensive efforts from the biomedical research community to improve targeted therapy designs and bring a substantial change in the treatment decisions. In the next era of genomic medicine, we anticipate that a clinically and biologically relevant molecular profile of each tumor will be obtained at diagnosis to guide therapy.",
keywords = "Diffuse large B-cell lymphomas, Gene expression profiling, Molecular classification, Molecular prognosis, Targeted therapy",
author = "Javeed Iqbal and {Naushad Qureishi}, Hina and Chengfeng Bi and Jiayu Yu and Alyssa Bouska and Joseph Rohr and Wang Chao and Kai Fu and Chan, {Wing C.} and Vose, {Julie Marie}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.blre.2015.08.002",
language = "English (US)",
volume = "30",
pages = "73--88",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Genomic signatures in B-cell lymphoma

T2 - How can these improve precision in diagnosis and inform prognosis?

AU - Iqbal, Javeed

AU - Naushad Qureishi, Hina

AU - Bi, Chengfeng

AU - Yu, Jiayu

AU - Bouska, Alyssa

AU - Rohr, Joseph

AU - Chao, Wang

AU - Fu, Kai

AU - Chan, Wing C.

AU - Vose, Julie Marie

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Current genomic technologies have immensely improved disease classification and prognostication of major subtypes of B-cell lymphomas. This novel genetic information has not only aided in diagnosis, but has also revealed a landscape of critical molecular events that determine the biological and clinical behavior of a lymphoma. In this review, we summarized the genetic characteristics of major subtypes of B-cell lymphomas, including diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), and mantle cell lymphoma (MCL). We illustrated how genomic profiling had identified molecular subgroups in DLBCL with varied clinical outcomes, and how a subset of genes defined prognosis in MCL and aided in BL diagnoses. We also highlighted some Phase II/III clinical trials using new therapeutic agents to determine clinical efficacy in novel molecular subgroups with distinct gene expression patterns. We believe that refinement of genomic signatures will require more intensive efforts from the biomedical research community to improve targeted therapy designs and bring a substantial change in the treatment decisions. In the next era of genomic medicine, we anticipate that a clinically and biologically relevant molecular profile of each tumor will be obtained at diagnosis to guide therapy.

AB - Current genomic technologies have immensely improved disease classification and prognostication of major subtypes of B-cell lymphomas. This novel genetic information has not only aided in diagnosis, but has also revealed a landscape of critical molecular events that determine the biological and clinical behavior of a lymphoma. In this review, we summarized the genetic characteristics of major subtypes of B-cell lymphomas, including diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), and mantle cell lymphoma (MCL). We illustrated how genomic profiling had identified molecular subgroups in DLBCL with varied clinical outcomes, and how a subset of genes defined prognosis in MCL and aided in BL diagnoses. We also highlighted some Phase II/III clinical trials using new therapeutic agents to determine clinical efficacy in novel molecular subgroups with distinct gene expression patterns. We believe that refinement of genomic signatures will require more intensive efforts from the biomedical research community to improve targeted therapy designs and bring a substantial change in the treatment decisions. In the next era of genomic medicine, we anticipate that a clinically and biologically relevant molecular profile of each tumor will be obtained at diagnosis to guide therapy.

KW - Diffuse large B-cell lymphomas

KW - Gene expression profiling

KW - Molecular classification

KW - Molecular prognosis

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84948763084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948763084&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2015.08.002

DO - 10.1016/j.blre.2015.08.002

M3 - Article

C2 - 26432520

AN - SCOPUS:84948763084

VL - 30

SP - 73

EP - 88

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 2

ER -